111 related articles for article (PubMed ID: 26914246)
1. Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes.
Di Savino A; Gaidano V; Palmieri A; Crasto F; Volpengo A; Lorenzatti R; Scaravaglio P; Manello A; Nicoli P; Gottardi E; Saglio G; Cilloni D; De Gobbi M
Br J Haematol; 2017 Feb; 176(3):491-495. PubMed ID: 26914246
[No Abstract] [Full Text] [Related]
2. Erythropoietin receptor in myelodysplastic syndrome and leukemia.
Takeshita A; Shinjo K; Naito K; Ohnishi K; Higuchi M; Ohno R
Leuk Lymphoma; 2002 Feb; 43(2):261-4. PubMed ID: 11999556
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of IGF-IR in malignant clonal cells in bone marrow of myelodysplastic syndromes.
He Q; Li X; Zhang Z; Zhang Q; Xu F; Yang L; Tao Y; Liu Y
Cancer Invest; 2010 Dec; 28(10):983-8. PubMed ID: 20569071
[TBL] [Abstract][Full Text] [Related]
4. Circulating erythropoietin in patients with myelodysplastic syndromes.
Jacobs A; Janowska-Wieczorek A; Caro J; Bowen DT; Lewis T
Br J Haematol; 1989 Sep; 73(1):36-9. PubMed ID: 2803975
[TBL] [Abstract][Full Text] [Related]
5. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells.
Kawabata H; Nakamaki T; Ikonomi P; Smith RD; Germain RS; Koeffler HP
Blood; 2001 Nov; 98(9):2714-9. PubMed ID: 11675342
[TBL] [Abstract][Full Text] [Related]
6. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes.
Bowen DT; Jacobs A; Cotes PM; Lewis TC
Eur J Haematol; 1990 Jan; 44(1):30-2. PubMed ID: 2307217
[TBL] [Abstract][Full Text] [Related]
7. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders.
Cortelezzi A; Colombo G; Pellegrini C; Silvestris I; Moronetti Mazzeo L; Bosari S; Lambertenghi Deliliers G; Fracchiolla NS
Am J Hematol; 2008 Jul; 83(7):531-9. PubMed ID: 18383321
[TBL] [Abstract][Full Text] [Related]
9. Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production.
Velegraki M; Papakonstanti E; Mavroudi I; Psyllaki M; Tsatsanis C; Oulas A; Iliopoulos I; Katonis P; Papadaki HA
Haematologica; 2013 Aug; 98(8):1206-15. PubMed ID: 23403315
[TBL] [Abstract][Full Text] [Related]
10. Marked erythroblastosis in myelodysplastic syndrome induced by gastric hemorrhaging.
Yoshimura S; Munakata W; Ikeda C; Matsushita H
Int J Hematol; 2018 Apr; 107(4):387-389. PubMed ID: 29188581
[No Abstract] [Full Text] [Related]
11. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.
Backx B; Broeders L; Hoefsloot LH; Wognum B; Löwenberg B
Leukemia; 1996 Mar; 10(3):466-72. PubMed ID: 8642863
[TBL] [Abstract][Full Text] [Related]
12. VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes.
Lubkova ON; Tzvetaeva NV; Momotyuk KS; Belkin VM; Manakova TE
Bull Exp Biol Med; 2011 May; 151(1):13-5. PubMed ID: 22442792
[TBL] [Abstract][Full Text] [Related]
13. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
14. T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone.
Vercauteren SM; Starczynowski DT; Sung S; McNeil K; Salski C; Jensen CL; Bruyere H; Lam WL; Karsan A
Br J Haematol; 2012 Feb; 156(3):409-12. PubMed ID: 25289412
[No Abstract] [Full Text] [Related]
15. [Significance of sTfR and sTfR/E levels in the assessment of bone marrow hematopoietic function in patients with myelodysplastic syndrome].
Yang B; Yang Y; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Dec; 34(12):1060-2. PubMed ID: 24369166
[No Abstract] [Full Text] [Related]
16. [Application of flow cytometry in detecting dysplasia of myelodysplastic syndromes].
Li J; He GS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1069-72. PubMed ID: 23998614
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
18. CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes: Potential Predictive Tools of Response to Erythropoietin Stimulating Agents.
Boggio F; Del Gobbo A; Barella M; Croci G; Cassin R; Reda G; Pettine L; Bandiera L; Bonoldi E; Riva M; Gianelli U
Pathobiology; 2021; 88(3):242-250. PubMed ID: 33588425
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome.
Yue LZ; Fu R; Wang HQ; Li LJ; Hu HR; Fu L; Shao ZH
Chin Med J (Engl); 2010 Aug; 123(15):2034-7. PubMed ID: 20819538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
